Daewoong Pharmaceutical expects sales to rise through its new drug introduced along with the new drug Fexuclue, a new drug for gastroesophageal reflux disease. This includes biosimilars such as Lexapro, Ogivri, and Alymsys, the No. 1 items in the antidepressant market.

According to industries on the 14th, Daewoong Pharmaceutical is planning to continue its performance increase through its new drug introduced this year. Last year, Daewoong Pharmaceutical recorded its highest-ever performance with sales of 1.1530 trillion won and operating profit of 88.9 billion won. The driving force behind the rise in sales is P-CAB gastroesophageal reflux disease, which was released this month. Fexuclu is expecting sal